Raymond James Has Pessimistic Outlook of TSE:MDP Q3 Earnings

Medexus Pharmaceuticals Inc. (TSE:MDP) – Investment analysts at Raymond James dropped their Q3 2026 earnings per share estimates for Medexus Pharmaceuticals in a report issued on Tuesday, January 7th. Raymond James analyst M. Freeman now anticipates that the company will post earnings of $0.22 per share for the quarter, down from their prior estimate of $0.24. Raymond James currently has a “Strong-Buy” rating and a $4.00 price target on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Raymond James also issued estimates for Medexus Pharmaceuticals’ Q4 2026 earnings at $0.23 EPS, FY2026 earnings at $0.89 EPS, FY2027 earnings at $0.88 EPS, FY2028 earnings at $0.80 EPS and FY2029 earnings at $0.77 EPS.

A number of other research firms also recently issued reports on MDP. Leede Financial set a C$8.25 target price on Medexus Pharmaceuticals and gave the company a “speculative buy” rating in a research report on Monday, September 30th. Alliance Global Partners raised Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, December 23rd. Two investment analysts have rated the stock with a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Strong Buy” and a consensus price target of C$5.25.

Medexus Pharmaceuticals Stock Performance

TSE:MDP opened at C$3.60 on Thursday. The stock’s 50-day simple moving average is C$2.72 and its 200 day simple moving average is C$2.50. The company has a market cap of C$88.31 million, a P/E ratio of 72.00 and a beta of 1.96. Medexus Pharmaceuticals has a 52-week low of C$1.47 and a 52-week high of C$3.60.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.